Investors Should Be Aware of Class Action Options
Levi & Korsinsky, LLP has brought to attention a significant class action lawsuit concerning Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), which aims to protect investors adversely affected by alleged securities fraud. This case highlights critical issues that may impact shareholders and emphasizes the urgency for affected stakeholders to consider their legal rights.
Understanding the Class Action Case
The litigation covers a period where investors are claimed to have suffered losses due to misleading statements from the company's executives. These statements are related to the handling of credit card fees associated with one of their flagship products, Eylea. The implications of these allegations could be profound, affecting not just the financial standings of the company but the integrity of its operations.
Key Allegations Posed in the Lawsuit
The complaint suggests that Regeneron engaged in practices that artificially inflated sales figures for Eylea. Specifically, it is alleged that Regeneron cooperated with distributors to suppress the visible costs of credit card transactions, creating a distorted view of the true selling price of their medication. Investors must understand that such practices, if proven true, could lead to significant financial ramifications for the company and its shareholders.
Your Rights as an Investor
For those affected, the deadline to engage with this legal recourse is fast approaching. Investors who have suffered losses in Regeneron during this specified timeframe should actively consider reaching out. The cut-off date is vital; March 10, 2025, has been established for investors to request court recognition as lead plaintiffs.
No Financial Burden
An important aspect of this class action is that there are no upfront costs associated with participation. Eligible investors can potentially receive compensation without any payment obligations, making it an accessible option for those who wish to seek restitution for their losses.
Why Work With Levi & Korsinsky?
Levi & Korsinsky is well-regarded in the field of securities litigation, having secured substantial settlements for shareholders over the last two decades. Their proven track record and extensive legal resources rank them among the top firms in the industry, making them a reliable partner for investors navigating complex legal challenges.
How to Reach Levi & Korsinsky
Stakeholders interested in learning more about the lawsuit and their own legal standing can consider contacting Joseph E. Levi, Esq. at (212) 363-7500. Engaging with a knowledgeable legal professional may provide valuable insights into how best to proceed.
Frequently Asked Questions
What is the lawsuit about?
The lawsuit concerns allegations of securities fraud involving misleading statements related to Regeneron's credit card practices for their product Eylea.
When is the deadline to act?
Investors have until March 10, 2025, to apply for lead plaintiff status in the class action.
Are there any costs to participate in the lawsuit?
No, there are no out-of-pocket costs for class members who wish to participate in the lawsuit.
How can I contact Levi & Korsinsky for more information?
Interested investors can call Joseph E. Levi, Esq. at (212) 363-7500 for detailed information about the case.
What should I do if I was affected by this issue?
If you have experienced losses related to Regeneron’s stock during the relevant timeframe, it’s essential to reach out to legal counsel to understand your rights and options.
